Answers are grounded in this paper and cite their sources.
This review discusses strategies for improving chirality generation in macrocyclic natural products, suggesting enhanced synthesis efficiency.
Macrocyclic natural products, including macrolactones, macrolactams, macrocyclic (depsi)peptides, and macrocyclic cyclophanes, occupy a chemical space that does not overlap significantly with that of traditional low molecular weight and sp²-carbon rich pharmaceuticals. Traditionally, total synthesis toward macrocyclic natural products has been typically based on installation of backbone stereogenic centers at early- to mid-stage and closure of the macrocyclic backbone at late stage. However, these synthesis strategies suffer from multiple concession steps, making them less attractive in terms of step-economy. In this review, we provide an overview of late-stage chirality generation strategies in macrocyclic natural product synthesis, embodying stereoselective functional group and/or skeletal transformations that take advantage of macrocyclic conformational constraints. Expanding our repertoire of transformations amenable to late-stage chirality generation as well as advancing controllability over the conformational property of macrocycles will facilitate future developments in the total synthesis of macrocyclic natural products.
No takes yet. Share an insight, caveat, or question.
Fuwa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: